Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025p -0.07% 35.25p 34.95p 35.65p 35.95p 35.25p 35.45p 349,286 16:06:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -32.7 -28.3 - 93.09

Motif Bio Share Discussion Threads

Showing 2301 to 2322 of 2325 messages
Chat Pages: 93  92  91  90  89  88  87  86  85  84  83  82  Older
DateSubjectAuthorDiscuss
22/2/2018
02:34
http://www.proactiveinvestors.co.uk/companies/stocktube/8785/motif-bio-to-present-at-prestigious-infectious-diseases-conference-8785.html Still plenty going on with the company...
ohisay
13/2/2018
14:07
AMP will be off loading more stock in June so no chance of a decent rise until after then.
encarter
10/2/2018
09:46
Why the large fall on Friday.
librayang0925
09/2/2018
10:47
Topped up.
seans66
06/2/2018
11:02
Good old Motif, as contrary as ever
l4z4rus
06/2/2018
10:55
"Methinks". Old English. Only ever seen in Shakespeare and Financial websites. Why? No-one knows, forsooth and thrice Yea.
small crow
06/2/2018
10:25
Is that blue I see in my sea of red? If it holds it'll be quite a bullish statement methinks.
chadders
06/2/2018
10:24
A rare spot of blue whilst murder is all around on the market dance floor
longshanks
06/2/2018
08:49
Nothing is guaranteed timw3 but there are reasons to believe they will approve: evidence is there of non-inferiority to vancomycin, which doesn't sound great but in reality is pretty good in an age of growing resistance government policies to encourage the development of new antibiotics, and not approving a new one might discourage further investment in new antibiotics and lead to adverse publicity for the FDA and the experts a particular role for Iclaprim in obese and renally impaired patients with ABSSSI where dose adjustment may not be necessary compared to vancomycin a less used mode of action which should make the development of resistance less of an issue, but of course it is still an issue, and makes it an alternative to use where there is resistance to vancomycin I am invested here and believe in the future of iclaprim. Also the potential use in other indications is important for the future. I am also impressed with the management of the company and the materials they are producing. I have said on another BB that even an idiot management team can be successful if the drug works and meets an unmet need, but now having seen what I regard as such a team in another company I can see how even a good drug and returns to shareholders can be delayed and lost in such cases. I have confidence in this team at Motif Bio. They are doing the right things, in my view.
gclark
06/2/2018
08:00
Down 4.6% i would call that a healthy correction!! And one that is very much needed for sustainability, hopefully a crash will be avoided!!!!!!!!
escapetohome
06/2/2018
07:56
going back to 20p imo FDA approval not guaranteed neither. OUCH
timw3
05/2/2018
21:56
hate trader you not scoring points down your local trying to get the bulls eye!! i know who you are son!!
timw3
05/2/2018
21:03
Tim, it doesn’t look like an ugly chart to me...read them properly...lots of support at 35.5.
flavio_monteiro
05/2/2018
20:33
dow crashing. see this going below 30p soon. ugly chart also
timw3
03/2/2018
08:38
From today's Interactive ---- Investor site Motif Bio (MTFB) 37.55p Antibiotics developer Motif Bio (MTFB) is reaching an important point in the development of its new antibiotic Iclaprim, which is focused on acute bacterial skin and skin structure infections (ABSSSI). Antibiotic resistance is a key topic in the healthcare sector so new antibiotics are essential. Iclaprim was originally discovered by Hoffman-La Roche, but Motif has adapted the development programme to address the reasons it failed to gain FDA approval in 2009. Iclaprim has shown that it is at least as good as existing antibiotics in treating skin infections, but without the side effects of the rivals. It can be used on very sick patients. The plan is to lodge a new drug application in the US during the first quarter of 2018. If things go smoothly, then there could be a commercial treatment by the end of 2018. Motif has secured a $20 million loan facility, which more than doubled the available cash. A shelf registration in the US will enable Motif, which is also listed on Nasdaq, to raise up to $80m over a three-year period, although it says that no fundraising is currently planned. The US hospital market will be targeted via a contract sales organisation, while in Europe a partner will be sought and they will provide milestone payments to help to finance the approvals process in the region. Moving towards approvals that confirm that Iclaprim is a commercial product should propel the share price upwards. -
gersemi
02/2/2018
21:03
MTFB 36p on AIM....equivalent 40p Finish on Nasdaq....
flavio_monteiro
02/2/2018
20:42
Normally means sacked!
small crow
02/2/2018
18:05
Never ideal if the CFO leaves and they don;t state why.
waterloo01
01/2/2018
07:59
I remember seeing several 70000ish buys as well
librayang0925
31/1/2018
18:09
It's not really that big is it. And the other?
small crow
31/1/2018
17:42
One with about 140000 shares
librayang0925
31/1/2018
15:25
Two very big buys
librayang0925
Chat Pages: 93  92  91  90  89  88  87  86  85  84  83  82  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180222 16:41:48